An antibody raised against Rho GTPase-activating protein 26 (ARHGAP26); a small G protein family protein, GRAF-1 regulates RhoA and CDC42. ARHGAP26 dysregulation is linked to numerous cancers, hematopoietic disorders, and auto-immune cerebellar ataxia.
Catalogue number crb2005623 Antibody Anti-GRAF-1 antibody Antigen Peptide KLH conjugated synthetic peptide crb1200848e Protein ID Q9UNA1 Human ARHGAP26 Aliases GRAF-1, Rho GTPase-activating protein 26, Rho-type GTPase-activating protein 26, GTPase-activating protein for RHOA and CDC42, GTPase regulator associated with focal adhesion kinase, Oligophrenin-1-like protein Cross-Reactivity Human Target Protein Species Human Host Species Rabbit Antibody Type Polyclonal Concentration 1mg/ml Target GRAF-1 Storage Stabilisers The product should be stored at -20°C for short term storage and long term storage. Avoid repeated freeze/ thaw cycles. Family Hominidae Disease Area Blood Cancer- Leukemia, juvenile myelomonocytic (JMML) Post-translational Modification Phosphorylated, Ubiquitinated Storage The product should be stored at -20°C for short term storage and long term storage. Avoid repeated freeze/ thaw cycles. References
Chen et al., (2019). SMURF1-mediated ubiquitination of ARHGAP26 promotes ovarian cancer cell invasion and migration. Exp Mol Med. 51(4): 1. PMID: 31004081.
Jiang et al., (2018). RhoA/ROCK/ARHGAP26 signaling in the eutopic and ectopic endometrium is involved in clinical characteristics of adenomyosis. J Int Med Res. 46(12): 5019. PMID: 30387365.
Li et al., (2019). Hypoxia-induced ARHGAP26 deficiency inhibits the proliferation and migration of human ductus arteriosus smooth muscle cell through activating RhoA-ROCK-PTEN pathway. J Cell Biochem. 120(6): 10106. PMID: 30592323.
Rho GTPase-activating protein 26 (ARHGAP26) is a GTPase-activating protein (GAP) for the small GTPases of the Rho family. ARHGAP26 converts RhoA (GTP-RhoA) and CDC42 (GTP-CDC42) to their inactive inactive GDP-bound forms. ARHGAP26 is critical for muscle development also plays important roles in malignant blood tumours and auto-immune cerebellar ataxia. ARHGAP26 expression is downregulated in patent human ductus arteriosus (DA) tissue.
ARHGAP26 is a tumour suppressor gene. ARHGAP26 expression is low in ovarian cancer tissues and is associated with a poor overall survival. ARHGAP26 is also inactivated in acute myeloid leukaemia (AML) and downregulated in glioblastoma. ARHGAP26 upregulation can inhibit lung metastasis. Translocation and point mutations of ARHGAP26 have been linked to the aggressive paediatric disorder juvenile myelomonocytic (JMML).